Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

Montalban, X; Hauser, SL; Kappos, L; Arnold, DL; Bar-Or, A; Comi, G; de Seze, J; Giovannoni, G; Hartung, H-P; Hemmer, B; Lublin, F; Rammohan, KW; Selmaj, K; Traboulsee, A; Sauter, A; Masterman, D; Fontoura, P; Belachew, S; Garren, H; Mairon, N; Chin, P; Wolinsky, JS; Investigators, ORATORIOC

View/Open

Published version (292.1Kb)

Volume

376

Pagination

209 - 220

DOI

10.1056/NEJMoa1606468

Journal

NEW ENGLAND JOURNAL OF MEDICINE

Issue

ISSN

0028-4793

Metadata

Show full item record

Authors

Montalban, X; Hauser, SL; Kappos, L; Arnold, DL; Bar-Or, A; Comi, G; de Seze, J; Giovannoni, G; Hartung, H-P; Hemmer, B

URI

http://qmro.qmul.ac.uk/xmlui/handle/123456789/18928

Collections

Centre for Neuroscience, Surgery and Trauma [459]

Licence information

From New England Journal of Medicine, Montalban X, et al., Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis, 376:209-220. DOI: 10.1056/NEJMoa1606468. Copyright © 2016 Massachusetts Medical Society. Reprinted with permission.